Last reviewed · How we verify
SCT-001 CAR-T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
SCT-001 CAR-T cells (SCT-001 CAR-T cells) — Shanghai Gynecologic Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SCT-001 CAR-T cells TARGET | SCT-001 CAR-T cells | Shanghai Gynecologic Oncology Group | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SCT-001 CAR-T cells CI watch — RSS
- SCT-001 CAR-T cells CI watch — Atom
- SCT-001 CAR-T cells CI watch — JSON
- SCT-001 CAR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). SCT-001 CAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/sct-001-car-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab